October 06, 2004
Genentech is the latest biotech company to be served with subpoenas relating to drug promotion. It is believed that the investigation concerns off-label marketing of Rituxan, a cancer drug. Doctors may prescribe drugs for any use but pharmaceutical companies may market them only for purposes approved by the FDA.
The subpoenas were issued by the Office of the United States Attorney for the Eastern District of Pennsylvania, according to a, October 5, 2004 report in Red Herring.